GlaxoSmithKline: quarterly earnings rise 4%
(CercleFinance.com) - GlaxoSmithKline reported higher operating profit on Wednesday as strong sales of vaccines offset the loss of exclusivity on the asthma drug Advair.
Sales in the second quarter were up 5% at 7.8 billion pounds, in constant currencies, while adjusted EPS rose by 4% to 30.5 pence.
Vaccines turnover grew 26%, and consumer healthcare sales grew 5%, the British drugmaker said.
GSK said it now expects 2019 adjusted EPS to decline in the range of -3% to -5%, at constant currencies, which is actually an improvement to the range previously given of an expected decline in adjusted EPS of -5% to -9%.
The shares were up 0.8% in London after these results.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Sales in the second quarter were up 5% at 7.8 billion pounds, in constant currencies, while adjusted EPS rose by 4% to 30.5 pence.
Vaccines turnover grew 26%, and consumer healthcare sales grew 5%, the British drugmaker said.
GSK said it now expects 2019 adjusted EPS to decline in the range of -3% to -5%, at constant currencies, which is actually an improvement to the range previously given of an expected decline in adjusted EPS of -5% to -9%.
The shares were up 0.8% in London after these results.
Copyright (c) 2019 CercleFinance.com. All rights reserved.